ArticleThe Journal of antimicrobial chemotherapy2018
Genomic analysis reveals different mechanisms of fusidic acid resistance in Staphylococcus aureus from Danish atopic dermatitis patients.
Article in The Journal of antimicrobial chemotherapy, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 45 citations in OpenAlex.
- The global prevalence of fusidic acid resistance in clinical isolates of Staphylococcus aureus: a systematic review and meta-analysis.Antimicrobial resistance and infection control · 2021Pooled it
- Antimicrobial Susceptibility Patterns and Biofilm Formation ofMicroorganisms · 2026Article
- Genomic epidemiology and phenotypic characterization of Staphylococcus aureus isolated from atopic dermatitis patients in South China.Scientific reports · 2025Article
- Exploration of the Fusidic Acid Structure Activity Space for Antibiotic Activity.Molecules (Basel, Switzerland) · 2025Article
- Structures of the Staphylococcus aureus ribosome inhibited by fusidic acid and fusidic acid cyclopentane.Scientific reports · 2024Article
- Experimental evolution ofmBio · 2024Article
- Superantigen Encoding Genes in Staphylococcus aureus Isolated from Lesional Skin, Non-Lesional Skin, and Nares of Patients with Atopic Dermatitis.Acta dermato-venereologica · 2024Article
- Adding Fuel to the Fire? The Skin Microbiome in Atopic Dermatitis.The Journal of investigative dermatology · 2024Review
- Isolation, characterization, and antimicrobial resistance profiles ofArchives of Razi Institute · 2024Article
- Comprehensive Genomic Characterization of Staphylococcus aureus Isolated from Atopic Dermatitis Patients in Japan: Correlations with Disease Severity, Eruption Type, and Anatomical Site.Microbiology spectrum · 2023Article
- Clinical relevance of topical antibiotic use in co-selecting for multidrug-resistantAntimicrobial agents and chemotherapy · 2023Article
- On-person adaptive evolution of Staphylococcus aureus during treatment for atopic dermatitis.Cell host & microbe · 2023Article
- Staphylococcal diversity in atopic dermatitis from an individual to a global scale.Cell host & microbe · 2023Article
- Molecular co-localization of multiple drugs in a nanoscopic delivery vehicle for potential synergistic remediation of multi-drug resistant bacteria.Scientific reports · 2022Article
- Nocturnal Birds of Prey as Carriers ofAntibiotics (Basel, Switzerland) · 2022Article
- Skin Microbiome in Patients with Hand Eczema and Healthy Controls: A Three-week Prospective Study.Acta dermato-venereologica · 2022Article
- Staphylococcal Communities on Skin Are Associated with Atopic Dermatitis and Disease Severity.Microorganisms · 2021Article
- RNase J1 and J2 Are Host-Encoded Factors for Plasmid Replication.Frontiers in microbiology · 2021Article
- Fusidic Acid Resistance Determinants in Methicillin-Resistant Staphylococcus aureus Isolated in Kuwait Hospitals.Medical principles and practice : international journal of the Kuwait University, Health Science Centre · 2021Article
- Targeted Screening of Lactic Acid Bacteria With Antibacterial Activity TowardFrontiers in microbiology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Staphylococcus aureus skin colonization is common in patients with atopic dermatitis (AD) and is associated with risk of skin infections. AD patients therefore often receive antibiotic treatments, including topical treatment with fusidic acid, which have been associated with resistance development. Objectives: To examine the prevalence of antibiotic resistance in S. aureus isolated from Danish AD patients, with a primary focus on fusidic acid resistance and the genetic mechanisms that underlie it. Methods: One hundred and thirty-eight S. aureus isolates collected from lesional skin (n = 54), non-lesional skin (n = 27) and anterior nares (n = 57) from 71 adult AD patients were included in the study. Isolates were tested for susceptibility to 17 selected antibiotics. S. aureus whole-genome sequences were used to examine the genetic determinants of fusidic acid resistance (fusA or fusE mutations or carriage of fusB or fusC genes). Results: One hundred and nine isolates (79%) were resistant to at least one of the tested antibiotics, with the most prevalent resistances being to penicillin (55%), fusidic acid (41%) and erythromycin (11%). The primary genetic mechanisms of fusidic acid resistance were carriage of fusC (57%) or mutations in fusA (38%). The most prevalent S. aureus lineage was ST1 (23%). All ST1 isolates carried fusC. Conclusions: S. aureus fusidic acid resistance, caused by either fusA mutations or fusC gene carriage, is a major concern among AD patients. Resistant S. aureus might spread from the patients to the community, indicating the need to reduce the use of fusidic acid in the treatment of AD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.